7-氧代-2,8-二氮杂螺[5.5]十一烷-2-羧酸 1,1-二甲基乙酯 | 923009-54-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 中文名称: 7-氧代-2,8-二氮杂螺[5.5]十一烷-2-羧酸 1,1-二甲基乙酯
• 中文别名: 7-氧代-2,8-二氮杂螺[5.5]十一烷-2-羧酸1,1-二甲基乙酯
• 英文名称: tert-Butyl 5-oxo-4,10-diazaspiro[5.5]undecane-10-carboxylate
• 英文别名: tert-butyl 1-oxo-2,8-diazaspiro[5.5]undecane-8-carboxylate
• CAS: 923009-54-5
• 化学式: C₁₄H₂₄N₂O₃
• 分子量: 268.356
• InChiKey: BCWUGEIFXRKYMP-UHFFFAOYSA-N

物化性质

• 沸点：
  438.0±28.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  7-氧代-2,8-二氮杂螺[5.5]十一烷-2-羧酸 1,1-二甲基乙酯 在 盐酸 、 水 、 三乙酰氧基硼氢化钠 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 生成 8-[1-(9-anthrylcarbonyl)piperidin-4-yl]-2-ethyl-2,8-diazaspiro[5.5]undecan-1-one
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors

  摘要：

  The co-crystal structure of the human acetyl-coenzyme A 2 (ACC2) carboxyl transferase domain and the reported compound CP-640186 (1b) suggested that two carbonyl groups are essential for potent ACC2 inhibition. By focusing on enhancing the interactions between the two carbonyl groups and the amino acid residues Gly(2162) and Glu(2230), we used ligand-and structure-based drug design to discover spirolactones bearing a 2-ureidobenzothiophene moiety (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.117
• 作为产物：
  描述：

  N-Boc-3-哌啶甲酸乙酯 在 氨 、 氢气 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， -78.0 ℃ 、500.01 kPa 条件下， 生成 7-氧代-2,8-二氮杂螺[5.5]十一烷-2-羧酸 1,1-二甲基乙酯
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors

  摘要：

  The co-crystal structure of the human acetyl-coenzyme A 2 (ACC2) carboxyl transferase domain and the reported compound CP-640186 (1b) suggested that two carbonyl groups are essential for potent ACC2 inhibition. By focusing on enhancing the interactions between the two carbonyl groups and the amino acid residues Gly(2162) and Glu(2230), we used ligand-and structure-based drug design to discover spirolactones bearing a 2-ureidobenzothiophene moiety (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.117

文献信息

• SPIRO-CYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1911753A1

  公开（公告）日：2008-04-16

  The present invention provides a compound represented by the formula (I): wherein E is an optionally substituted cyclic group; D is a carbonyl group or a sulfonyl group; A is CH or N; ring P is an optionally further substituted 5- to 7-membered ring; ring Q is an optionally further substituted 5- to 7-membered nonaromatic ring; and ring R is an optionally further substituted and optionally condensed 5- to 7-membered nonaromatic ring, or a salt thereof. The compound of the present invention has an ACC inhibitory activity, is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and has superior properties in the efficacy, duration of activity, specificity, low toxicity and the like.

  本发明提供了一种由以下式（I）表示的化合物： 其中 E是一个可选择地取代的环状基团； D是一个羰基团或磺酰基团； A是CH或N； 环P是一个可选择进一步取代的5至7元环； 环Q是一个可选择进一步取代的5至7元非芳香环； 环R是一个可选择进一步取代和可选择缩合的5至7元非芳香环，或其盐。本发明的化合物具有ACC抑制活性，对于肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌肉萎缩等的预防或治疗具有用处，并且在功效、持续活性、特异性、低毒性等方面具有优越性能。
• Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
  申请人：Eckhardt Matthias

  公开号：US20110275595A1

  公开（公告）日：2011-11-10

  The present invention relates to compounds defined by formula I wherein the groups R 1 , Y 1 to Y 4 , V, W, and X are defined as in claim 1 , possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.

  本发明涉及由式I定义的化合物，其中R1，Y1至Y4，V，W和X基团的定义如权利要求书中所述，具有有价值的药理活性。特别是这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制的疾病，例如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
  申请人：Eckhardt Matthias

  公开号：US20110028445A1

  公开（公告）日：2011-02-03

  The present invention relates to compounds defined by formula (I) wherein the groups A, B, X, m, n and o are defined as in claim 1 , possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

  本发明涉及由式(I)定义的化合物，其中A，B，X，m，n和o的基团如权利要求1中所定义，具有有价值的药理活性。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以通过抑制该酶而受到影响的疾病，如代谢性疾病，特别是2型糖尿病，肥胖症和血脂异常。
• UREA DERIVATIVES OF BENZOMORPHANES AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2245014A1

  公开（公告）日：2010-11-03
• UREA DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2350068B1

  公开（公告）日：2017-08-30